Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Ann Rheum Dis
1998 Oct 01;5710:602-5. doi: 10.1136/ard.57.10.602.
Show Gene links
Show Anatomy links
Hyaluronan production in human rheumatoid fibroblastic synovial lining cells is increased by interleukin 1 beta but inhibited by transforming growth factor beta 1.
Kawakami M
,
Suzuki K
,
Matsuki Y
,
Ishizuka T
,
Hidaka T
,
Konishi T
,
Matsumoto M
,
Kataharada K
,
Nakamura H
.
???displayArticle.abstract???
OBJECTIVES: To investigate the regulatory roles of interleukin 1 beta (IL1 beta), tumour necrosis factor alpha (TNF alpha), interferon gamma (IFN gamma) or transforming growth factor beta 1 (TGF beta 1) on hyaluronan (HA) synthesis by human fibroblastic synovial lining cells.
METHODS: Concentrations of HA in culture supernatants of fibroblastic synovial lining cell line (RAMAK-1 cell line) with or without stimulation by IL1 beta, TNF alpha, IFN gamma or TGF beta 1 were measured by sandwich binding protein assay. Levels of HA synthase mRNA of the cells with or without stimulation were detected by reverse transcribed polymerase chain reaction. Molecular weights of HA in the culture supernatants of the cells with or without stimulation were measured using high performance gel permeation liquid chromatography.
RESULTS: HA synthesis by the cells was not significantly augmented by TNF alpha or by IFN gamma. It was significantly stimulated by IL1 beta but inhibited by TGF beta 1. Molecular weights of HA in the culture supernatants of the cells were unchanged by stimulation with TNF alpha. They were remarkably increased by stimulation with IL1 beta and IFN gamma, but reduced with TGF beta 1.
CONCLUSION: IL 1 beta is an up regulator of HA synthesis, while TGF beta 1 is a down regulator. HA production in the synovial lining cells of inflamed joints (for example, rheumatoid arthritis) might be regulated by the balance of these cytokines.
Allen,
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta.
1990, Pubmed
Allen,
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta.
1990,
Pubmed
Aruffo,
CD44 is the principal cell surface receptor for hyaluronate.
1990,
Pubmed
Bartolazzi,
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.
1994,
Pubmed
Brandes,
Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals.
1991,
Pubmed
Dixon,
Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee.
1988,
Pubmed
Elford,
Induction of swelling, synovial hyperplasia and cartilage proteoglycan loss upon intra-articular injection of transforming growth factor beta-2 in the rabbit.
1992,
Pubmed
Engström-Laurent,
Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis mass and morning stiffness.
1987,
Pubmed
Gotoh,
Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats.
1993,
Pubmed
Grecomoro,
Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo.
1987,
Pubmed
Haubeck,
Transforming growth factor beta 1, a major stimulator of hyaluronan synthesis in human synovial lining cells.
1995,
Pubmed
Itano,
Molecular cloning of human hyaluronan synthase.
1996,
Pubmed
,
Xenbase
Kawaguchi,
Cytokine regulation of prolyl 4-hydroxylase production in skin fibroblast cultures from patients with systemic sclerosis: contribution to collagen synthesis and fibrosis.
1992,
Pubmed
Kawakami,
Inhibition of Fas antigen-mediated apoptosis of rheumatoid synovial cells in vitro by transforming growth factor beta 1.
1996,
Pubmed
Kawakami,
A novel synoviocyte line (RAMAK-1), derived from a patient with rheumatoid arthritis.
1998,
Pubmed
Kuruvilla,
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.
1991,
Pubmed
Laurent,
Hyaluronan.
1992,
Pubmed
Massagué,
The transforming growth factor-beta family.
1990,
Pubmed
Miller,
Use of Na-hyaluronate during intraocular lens implantation in rabbits.
1977,
Pubmed
Namiki,
Therapeutic effect of intra-articular injection of high molecular weight hyaluronic acid on osteoarthritis of the knee.
1982,
Pubmed
Oksala,
Expression of proteoglycans and hyaluronan during wound healing.
1995,
Pubmed
Peyron,
Intraarticular hyaluronan injections in the treatment of osteoarthritis: state-of-the-art review.
1993,
Pubmed
Pitsillides,
Hyaluronan concentration in non-inflamed and rheumatoid synovium.
1994,
Pubmed
Spicer,
Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family.
1998,
Pubmed
,
Xenbase
Sporn,
Transforming growth factor-beta: recent progress and new challenges.
1992,
Pubmed
Suzuki,
Stimulation of hyaluronan biosynthesis by platelet-derived growth factor-BB and transforming growth factor-beta 1 involves activation of protein kinase C.
1995,
Pubmed
Swann,
Role of hyaluronic acid in joint lubrication.
1974,
Pubmed
Thorbecke,
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice.
1992,
Pubmed
Underhill,
CD44 positive macrophages take up hyaluronan during lung development.
1993,
Pubmed
Vuorio,
Synthesis of underpolymerized hyaluronic acid by fibroblasts cultured from rheumatoid and non-rheumatoid synovitis.
1982,
Pubmed
Worrall,
Morphological localization of hyaluronan in normal and diseased synovium.
1991,
Pubmed
